Cardinal Health/$CAH
1D1W1MYTD1Y5YMAX
Capital at risk
About Cardinal Health
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
- Ticker
- $CAH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 61,344
- Headquarters
- Dublin, United States
- Website
- www.cardinalhealth.com
Cardinal Health Metrics
BasicAdvanced
$54B
32.18
$7.23
0.52
$2.05
0.89%
Price and volume
Market cap
$54B
Beta
0.52
52-week high
$258.30
52-week low
$145.87
Average daily volume
1.7M
Dividend rate
$2.05
Financial strength
Current ratio
0.883
Quick ratio
0.425
Long term debt to equity
-2.906
Total debt to equity
-3.67
Dividend payout ratio (TTM)
28.65%
Interest coverage (TTM)
9.45%
Profitability
EBITDA (TTM)
4,244
Gross margin (TTM)
3.84%
Net profit margin (TTM)
0.67%
Operating margin (TTM)
1.29%
Effective tax rate (TTM)
21.57%
Revenue per employee (TTM)
$4,140,000
Management effectiveness
Return on assets (TTM)
3.72%
Return on equity (TTM)
-63.64%
Valuation
Price to earnings (TTM)
32.178
Price to revenue (TTM)
0.216
Price to book
-18.8
Price to tangible book (TTM)
-3.28
Price to free cash flow (TTM)
12.134
Free cash flow yield (TTM)
8.24%
Free cash flow per share (TTM)
19.174
Dividend yield (TTM)
0.88%
Forward dividend yield
0.89%
Growth
Revenue change (TTM)
14.23%
Earnings per share change (TTM)
12.09%
3-year revenue growth (CAGR)
7.44%
10-year revenue growth (CAGR)
7.66%
3-year earnings per share growth (CAGR)
79.03%
10-year earnings per share growth (CAGR)
5.28%
3-year dividend per share growth (CAGR)
1.00%
10-year dividend per share growth (CAGR)
2.44%
What the Analysts think about Cardinal Health
Analyst ratings (Buy, Hold, Sell) for Cardinal Health stock.
Analyst projections of the future price of Cardinal Health stock.
Bulls say / Bears say
Cardinal issued strong fiscal 2027 guidance, targeting non-GAAP EPS of $12.40–$12.60, or 13%–15% growth, above its long-term target; it also expects $3.5–$4.0 billion of adjusted free cash flow. (Cardinal Health)
Specialty pharmaceuticals remain a strong earnings driver: fiscal Q4 Pharmaceutical and Specialty Solutions profit rose 21%, and Reuters reported that demand for costly specialty medicines and biosimilars helped Cardinal raise its fiscal 2026 profit outlook. (Reuters)
Cardinal is broadening beyond traditional drug distribution through its Other businesses, whose fiscal 2027 profit is expected to grow 15%–18%; the company also authorized an additional $5 billion of share repurchases, supporting per-share earnings and capital returns. (Cardinal Health)
A meaningful portion of fiscal 2026 earnings benefited from a one-time $100 million IEEPA tariff refund; management’s fiscal 2027 growth comparison excludes that benefit, creating a less favorable underlying earnings bridge. (Cardinal Health)
The Global Medical Products and Distribution segment remains exposed to trade and volume pressure: fiscal Q3 profit fell 36% year over year because of tariffs, while fiscal Q4 revenue declined 2% amid lower distribution volumes. (Cardinal Health)
Cardinal’s core Pharmaceutical and Specialty Solutions business still faces execution and demand-conversion risk: fiscal Q3 total sales missed expectations despite an adjusted EPS beat, and fiscal 2027 guidance calls for only 3%–5% segment revenue growth. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Cardinal Health Financial Performance
Revenues and expenses
Cardinal Health Earnings Performance
Company profitability
Upcoming events
Cardinal Health News
AllArticlesVideos
Funds containing Cardinal Health
AllEURGBPUSD
Fund name | Fund size | $CAH weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.79% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.91% |
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 0.41% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 0.41% |
iShares Edge S&P 500 Minimum Volatility$SPMV | $1.9B | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.